

Accepted Manuscript

Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality? A critical question that we are only just beginning to answer

Joel M. Gelfand, MD MSCE

PII: S0190-9622(18)30500-0

DOI: [10.1016/j.jaad.2018.03.046](https://doi.org/10.1016/j.jaad.2018.03.046)

Reference: YMJD 12435

To appear in: *Journal of the American Academy of Dermatology*



Please cite this article as: Gelfand JM, Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality? A critical question that we are only just beginning to answer, *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2018.03.046.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Invited Commentary***Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality? A critical question that we are only just beginning to answer***

Joel M Gelfand, MD MSCE

Professor of Dermatology, Professor of Epidemiology

Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit

Director, Psoriasis and Phototherapy Treatment Center

University of Pennsylvania Perelman School of Medicine

3400 Civic Center Boulevard

7th Floor, South Tower Office # 730

Philadelphia, PA 19104

Joel.Gelfand@uphs.upenn.edu

Word count 918

Reference count: 8

Funding: JMG is supported by NIH/NIAMS K24-AR064310

Disclosure: Dr. Gelfand served as a consultant for BMS, Boehringer Ingelheim, GSK, Janssen Biologics, Menlo Therapeutics, Novartis Corp, Regeneron, Dr Reddy's labs, UCB (DSMB), Sanofi and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly and Ortho Dermatologics. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma. Dr Gelfand is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology.

Download English Version:

<https://daneshyari.com/en/article/8714959>

Download Persian Version:

<https://daneshyari.com/article/8714959>

[Daneshyari.com](https://daneshyari.com)